ZyVersa raises $1M via convertible notes and warrants for working capital

ZyVersa Therapeutics, Inc.

Issued $1M aggregate principal 10% convertible promissory notes, maturing in 12 months, with a $0.02 floor price on conversion.
Notes convertible at 80% of the lowest daily VWAP during the 10 trading days prior to conversion notice.
Series A-4 warrants exercisable six months post-issuance, expiring in 5 years; exercise price linked to qualified offering or VWAP.
Proceeds to be used for working capital; obligations guaranteed by subsidiary ZyVersa Therapeutics Operating, Inc.
Securities sold to accredited investors in a private placement under Section 4(a)(2) and Regulation D.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ZyVersa Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $1 million (effective 2026-02-27).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: $1 million
Effective: 2026-02-27

Exact text from the filing

On February 27, 2026, ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company issued and sold to the Purchasers convertible promissory notes in an aggregate principal amount of $1 million (the “Notes”) and Series A-4 Common Stock Purchase Warrants (the “Warrants”) to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).

View on SEC.gov

336 material agreements filed in the last 30 days. Browse all material agreements →

ZyVersa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-008994

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.